Search

Your search keyword '"I. Rivolta"' showing total 82 results

Search Constraints

Start Over You searched for: Author "I. Rivolta" Remove constraint Author: "I. Rivolta"
82 results on '"I. Rivolta"'

Search Results

1. AKI - Experimental

2. A RABBIT MODEL OF UREMIA-INDUCED CARDIOMYOPATHY

4. CARDIAC ACTIVITY MODIFICATION UREMIA-RELATED: A RABBIT MODEL

6. Si-based Nanoparticles: a biocompatibility study

7. SLN As Vehicle For A Model Drug: A Biophysical Study

8. Uptake And Intracellular Distribution Of Functionalized Iron Oxide Nanoparticles

9. Ion Channels as Targets for Drugs

11. In silico assessment of Y1795C and Y1795H SCN5A mutations. Implication for inherited arrhythmogenic syndrome

12. Computer Simulation of wild-type and mutant human cardiac Na+ current

13. NaV1.5 autoantibodies in Brugada syndrome: pathogenetic implications.

14. A novel de novo HCN2 loss-of-function variant causing developmental and epileptic encephalopathy treated with a ketogenic diet.

15. Unravelling Novel SCN5A Mutations Linked to Brugada Syndrome: Functional, Structural, and Genetic Insights.

16. A novel KCNC1 gain-of-function variant causing developmental and epileptic encephalopathy: "Precision medicine" approach with fluoxetine.

17. Automated Patch-Clamp and Induced Pluripotent Stem Cell-Derived Cardiomyocytes: A Synergistic Approach in the Study of Brugada Syndrome.

18. Alterations of the Sialylation Machinery in Brugada Syndrome.

19. T-Type Calcium Channels: A Mixed Blessing.

20. Functional Characterization of Two Variants at the Intron 6-Exon 7 Boundary of the KCNQ2 Potassium Channel Gene Causing Distinct Epileptic Phenotypes.

21. Role of the Air-Blood Barrier Phenotype in Lung Oxygen Uptake and Control of Extravascular Water.

22. Do the functional properties of HCN1 mutants correlate with the clinical features in epileptic patients?

23. Dietary Nanoparticles Interact with Gluten Peptides and Alter the Intestinal Homeostasis Increasing the Risk of Celiac Disease.

24. Novel SCN5A p.Val1667Asp Missense Variant Segregation and Characterization in a Family with Severe Brugada Syndrome and Multiple Sudden Deaths.

25. Effect of the ketogenic diet in excitable tissues.

26. Brugada syndrome genetics is associated with phenotype severity.

27. Gabapentin treatment in a patient with KCNQ2 developmental epileptic encephalopathy.

28. Rational design of a mutation to investigate the role of the brain protein TRIP8b in limiting the cAMP response of HCN channels in neurons.

29. Innovative Therapies and Nanomedicine Applications for the Treatment of Alzheimer's Disease: A State-of-the-Art (2017-2020).

30. Cardiac and neuronal HCN channelopathies.

31. GSTM3 variant is a novel genetic modifier in Brugada syndrome, a disease with risk of sudden cardiac death.

32. HCN ion channels and accessory proteins in epilepsy: genetic analysis of a large cohort of patients and review of the literature.

33. APOA-1Milano muteins, orally delivered via genetically modified rice, show anti-atherogenic and anti-inflammatory properties in vitro and in Apoe -/- atherosclerotic mice.

34. HCN1 mutation spectrum: from neonatal epileptic encephalopathy to benign generalized epilepsy and beyond.

35. A novel de novo HCN1 loss-of-function mutation in genetic generalized epilepsy causing increased neuronal excitability.

36. Tissue specificity of mitochondrial adaptations in rats after 4 weeks of normobaric hypoxia.

37. SCN4A as modifier gene in patients with myotonic dystrophy type 2.

38. Modulation of the intrinsic neuronal excitability by multifunctional liposomes tailored for the treatment of Alzheimer's disease.

39. A Novel KCNJ2 Mutation Identified in an Autistic Proband Affects the Single Channel Properties of Kir2.1.

40. 'In Vitro', 'In Vivo' and 'In Silico' Investigation of the Anticancer Effectiveness of Oxygen-Loaded Chitosan-Shelled Nanodroplets as Potential Drug Vector.

41. The expression of the rare caveolin-3 variant T78M alters cardiac ion channels function and membrane excitability.

42. Simultaneous overexpression of human E5NT and ENTPD1 protects porcine endothelial cells against H 2 O 2 -induced oxidative stress and cytotoxicity in vitro.

43. Pharmacological and Biochemical Characterization of TLQP-21 Activation of a Binding Site on CHO Cells.

44. JMV5656, A Novel Derivative of TLQP-21, Triggers the Activation of a Calcium-Dependent Potassium Outward Current in Microglial Cells.

45. Dextran-shelled oxygen-loaded nanodroplets reestablish a normoxia-like pro-angiogenic phenotype and behavior in hypoxic human dermal microvascular endothelium.

46. Simultaneous Overexpression of Functional Human HO-1, E5NT and ENTPD1 Protects Murine Fibroblasts against TNF-α-Induced Injury In Vitro.

47. Acetylation mediates Cx43 reduction caused by electrical stimulation.

48. Chitosan-shelled oxygen-loaded nanodroplets abrogate hypoxia dysregulation of human keratinocyte gelatinases and inhibitors: New insights for chronic wound healing.

49. The effect of exogenous surfactant on alveolar interdependence.

50. SCN4A mutation as modifying factor of myotonic dystrophy type 2 phenotype.

Catalog

Books, media, physical & digital resources